Abstract
Edoxaban is a factor Xa inhibitor that is approved for prevention of stroke in individuals with atrial fibrillation and treatment of venous thromboembolic disease at once daily 60 mg dose for individuals with normal renal function. A decrease of dose to 30 mg is recommended for those with moderate renal insufficiency, weight ≤ 60 kg or simultaneous administration of strong P-glycoprotein inhibitors. At this time, it is not recommended for use in persons with either end stage renal disease or with GFR exceeding 95 mL/min. Shorter half-life averaging 8-10 hours may translate into a safer profile. With a fast onset of action of ~1.5 hours and relatively high bioavailability, edoxaban is an alternative for patients who may not be good candidates for warfarin therapy due to multiple limitations that vitamin K anticoagulation entails. No clear benefits of edoxaban have been reported to date compared to the other available factor Xa inhibitors.
Keywords: Edoxaban, oral anticoagulation, pharmacodynamics, pharmacokinetics.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy
Volume: 13 Issue: 2
Author(s): Maryna Popp Switzer, Priyanka Wani, Sucheta Gosavi and Debabrata Mukherjee
Affiliation:
Keywords: Edoxaban, oral anticoagulation, pharmacodynamics, pharmacokinetics.
Abstract: Edoxaban is a factor Xa inhibitor that is approved for prevention of stroke in individuals with atrial fibrillation and treatment of venous thromboembolic disease at once daily 60 mg dose for individuals with normal renal function. A decrease of dose to 30 mg is recommended for those with moderate renal insufficiency, weight ≤ 60 kg or simultaneous administration of strong P-glycoprotein inhibitors. At this time, it is not recommended for use in persons with either end stage renal disease or with GFR exceeding 95 mL/min. Shorter half-life averaging 8-10 hours may translate into a safer profile. With a fast onset of action of ~1.5 hours and relatively high bioavailability, edoxaban is an alternative for patients who may not be good candidates for warfarin therapy due to multiple limitations that vitamin K anticoagulation entails. No clear benefits of edoxaban have been reported to date compared to the other available factor Xa inhibitors.
Export Options
About this article
Cite this article as:
Switzer Popp Maryna, Wani Priyanka, Gosavi Sucheta and Mukherjee Debabrata, Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (2) . https://dx.doi.org/10.2174/187152571302151217130638
DOI https://dx.doi.org/10.2174/187152571302151217130638 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Unsafe Abortion: The Silent Endemic; An Avoidable Cause of Maternal Mortality. A Review
Current Women`s Health Reviews Propranolol Safety Profile in Children
Current Drug Safety Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Letters in Drug Design & Discovery Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Advances in Drug Safety
Current Pharmaceutical Design Focusing the Controversies in Budd-Chiari Syndrome Management
The International Journal of Gastroenterology and Hepatology Diseases The Implication of Pseudomonas aeruginosa Biofilms in Infections
Inflammation & Allergy - Drug Targets (Discontinued) Treatment of Pulmonary Edema by ENaC Activators/Stimulators
Current Molecular Pharmacology Ethical Considerations in Conducting Pediatric and Neonatal Research in Clinical Pharmacology
Current Pharmaceutical Design PEDF in Angiogenic Eye Diseases
Current Molecular Medicine Formulation Considerations of Gadolinium Lipid Nanoemulsion for Intravenous Delivery to Tumors in Neutron-Capture Therapy
Current Drug Delivery Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Effect of Direct-Acting Antiviral Drugs on Erectile Functions among Hepatitis C Patients: A Prospective Interventional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design Impact of Mast Cell Chymase on Renal Disease Progression
Current Hypertension Reviews Diagnosis of Systemic Lupus Erythematosus in an Unusual Presentation: What a Primary Care Physician Should Know
Current Rheumatology Reviews Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy